Thoughts as to whether A3-71 would be effective on the 20% that A-2-73 is not effective on?
Good evidence from lab rats dosed with Anavex 3-71 show that it will have both wider and stronger therapeutic applications than Anavex 2-73. But I have no understandings of how it might work for the minority of Alzheimer's patients that Anavex 2-73 may not work for (if at all for them).
That's because I don't fully understand the exact, precise, molecular-level ways the Anavex sigma-1 receptor agonists work (no one does). I'm talking about the exact ways the molecules bind, then facilitate the many, various reactions resulting in normalized neuron function.
Regardless, they do make things better, and at least on a surface level we know how it happens. Good enough. Anavex 2-73 by itself, and more likely Anavex 3-71, together, will change 21st-century medicine more significantly than did antibiotics in the last century.